Companion Medical said yesterday that it won CE Mark approval in the European Union for its InPen smart insulin pen and associated diabetes management smartphone application.
The company’s InPen system consists of a smart insulin injection pen that connects with an integrated diabetes management app.
The InPen application displays aggregated glucose, insulin and meal data and offers in depth daily views to improve adherence and glucose control for individuals with diabetes, the company said.
“We look forward to introducing more sophisticated smart pen technology with integrated diabetes management tools to people with diabetes in Europe. Our mission is to empower people living with diabetes and their healthcare providers with easy-to-use solutions that improve outcomes at a lower cost. With diabetes, the greatest challenge is knowing how much insulin to take and when to take it. The InPen system gives people with diabetes the tools they need to answer those questions precisely and accurately. Healthcare providers need actionable, reliable data from their insulin pen users, and now finally have that through Insights by InPen, our integrated diabetes management report,” CEO Sean Saint said in a press release.
Earlier this month, Companion Medical said that it won FDA clearance for the Android version of its InPen app.
